Form 4: BioCryst Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
BioCryst Pharmaceuticals' Chief Commercial Officer, Charles K. Gayer, sold 8,251 shares to cover tax obligations related to vesting restricted stock units.
Summary
- Charles K. Gayer, the Chief Commercial Officer of BioCryst Pharmaceuticals, sold 8,251 shares of common stock on December 14, 2024.
- The sale was executed at a price of $7.53 per share.
- This transaction was not a discretionary sale but rather a withholding of shares by the company to cover tax obligations arising from the vesting of previously granted restricted stock units.
- Following the transaction, Mr. Gayer directly owns 300,057 shares of BioCryst Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment regarding the company's performance or outlook.
Industry Context
Form 4 filings are a routine part of corporate governance and provide transparency into the transactions of company insiders. This filing indicates a standard tax-related transaction and does not suggest any change in the company's outlook or performance.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, such as BioCryst, and are required by the SEC to ensure transparency in insider trading.
- Similar filings are made by executives at comparable companies like Vertex Pharmaceuticals (VRTX) and Incyte (INCY) when they engage in stock transactions.
- The sale of shares to cover tax obligations is a common occurrence among executives who receive stock-based compensation, and this transaction is consistent with industry norms.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- The sale does not indicate any change in the company's performance or outlook.
Key Dates
| Date | Description |
|---|---|
| 12/14/2024 | Date of the stock sale transaction. |
| 12/17/2024 | Date the Form 4 was signed. |
Keywords
BioCryst Pharmaceuticals, BCRX, insider trading, Form 4, stock sale, executive, tax withholding, restricted stock units, Charles K. Gayer, Chief Commercial Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.